Market Overview

UPDATE: Bank Of America Reiterates On Pacira Pharmaceuticals On Positive Survey Results

Share:

In a report published Thursday, Bank of America analyst Steve Byrne reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised the price target from $86.00 to $104.00.

In the report, Bank of America noted, “We are raising our PO to $104 (from $86) based on positive results from our Exparel survey, including a meaningful change in the outlook from anesthesiologists and expectations for significant revenue growth. We see upside from use in the nerve block indication (March 5, 2015 PDUFA date) as anesthesiologists in our survey stated they would use Exparel in roughly half of their nerve block procedures if approved.

"We modestly adjusted our peak market share in nerve block to 25% (from 20%) and increased our 2021 peak sales to $2.3bn (from $2.1bn), which assumes some IP extension potential (spray based technology would extend IP to 2031) and expansion of PCRX' manufacturing capacity (readily replicable in our view). We see upside from other DepoFoam–derived products such as NSAIDs.”

Pacira Pharmaceuticals closed on Wednesday at $85.14.

Latest Ratings for PCRX

DateFirmActionFromTo
Nov 2020WedbushMaintainsOutperform
Sep 2020Northland Capital MarketsUpgradesMarket PerformOutperform
Sep 2020NeedhamMaintainsBuy

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

 

Related Articles (PCRX)

View Comments and Join the Discussion!

Posted-In: Bank of America Steve ByrneAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
THOWedbushInitiates Coverage On107.0
WGOWedbushInitiates Coverage On67.0
WLLMKM PartnersInitiates Coverage On30.0
ABNBAtlantic EquitiesInitiates Coverage On75.0
PGRKeefe, Bruyette & WoodsUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com